The move, announced Thursday, escalates the competition between the two pharmaceutical giants for a critical advantage in the highly lucrative weight-loss drug market.

Vertex should earn other important approvals through 2030 that could jolt its stock price. It's developing a treatment called zimislecel for type 1 diabetes (T1D), and the therapy is showing the ability to restore patients' insulin production in clinical trials.

I don’t know what to say about Pfizer. I mean, it’s got that yield of 7%. It bought that Seagen. I thought it was going to change it.

Two of the world’s largest pharmaceutical companies, Pfizer (New York, US) and Roche (Basel, Switzerland), have unveiled more than $10bn in biotech acquisitions within days of each other, emphasising the intensifying competition in obesity and liver disease therapies and highlighting how US policy on manufacturing,

Pfizer (PFE) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended September 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture,